7.85  1.805 (29.86%)		06-30 16:00
Open: 6.255 High: 7.85 Volume: 980,242		Pre. Close: 6.045 Low: 5.6342 Market Cap: 11(M)

Short term
Mid term
Targets	6-month :	41.65	1-year :	48.64
Resists	First :	35.65	Second :	41.65
Pivot price	30.68
Supports	First :	17.1	Second :	5.63
MAs	MA(5) :	33.94	MA(20) :	28.9
	MA(100) :	0	MA(250) :	0
MACD	MACD :	0	Signal :	0
%K %D	K(14,3) :	88.6	D(3) :	93.2
RSI	RSI(14): 70.9
52-week	High :	35.65	Low :	22.39

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ SNPX ] has closed below upper band by 42.5%. Bollinger Bands are 0% narrower than normal.

If tomorrow:	Open lower	Open higher
High:	35.23 - 35.41	35.41 - 35.55
Low:	31.53 - 31.71	31.71 - 31.84
Close:	31.56 - 31.85	31.85 - 32.07

Synaptogenix, Inc. operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. It focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. Synaptogenix, Inc. has licensing agreements with Stanford University; Icahn School of Medicine at Mount Sinai; and The Board of Trustees of the Leland Stanford Junior University. The company was incorporated in 2012 and is headquartered in New York, New York.

Tue, 01 Jul 2025
Traditional Nasdaq Company Transforms into TAO Crypto Powerhouse: What This Means for AI Innovation - Stock Titan

Thu, 26 Jun 2025
Synaptogenix Makes Bold Move into AI Crypto, Rebrands as TAO Synergies with New Revenue Strategy - Stock Titan

Thu, 26 Jun 2025
Synaptogenix Announces Name Change to TAO Synergies and New Tick - GuruFocus

Tue, 24 Jun 2025
Synaptogenix begins TAO acquisition as part of crypto treasury strategy - Investing.com

Tue, 24 Jun 2025
Synaptogenix (SNPX) Initiates Cryptocurrency Strategy with TAO A - GuruFocus

Mon, 09 Jun 2025
Synaptogenix (SNPX) Unveils AI-Focused Cryptocurrency Strategy | SNPX Stock News - GuruFocus

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Outperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	0 (M)
Shares Float	0 (M)
Held by Insiders	0 (%)
Held by Institutions	0 (%)
Shares Short	0 (K)
Shares Short P.Month	0 (K)

EPS	0
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	0 %
Return on Equity (ttm)	0 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	0
Qtrly Earnings Growth	0 %
Operating Cash Flow	0 (M)
Levered Free Cash Flow	0 (M)

PE Ratio	0
PEG Ratio	0
Price to Book value	0
Price to Sales	0
Price to Cash Flow	0

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.